West Nile virus vaccine - sanofi pasteur

Drug Profile

West Nile virus vaccine - sanofi pasteur

Alternative Names: ChimeriVax-West Nile; ChimeriVax-WN02

Latest Information Update: 07 Apr 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Acambis
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended West Nile virus infections

Most Recent Events

  • 25 Sep 2008 Acambis has been acquired by sanofi pasteur
  • 13 Nov 2007 Acambis and sanofi pasteur enter into an exclusive global collaboration agreement for the West Nile virus vaccine
  • 12 Sep 2006 Immunogenicity and adverse event data from a phase II trial released by Acambis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top